石药集团(01093.HK):安尼妥单抗联合注射用多西他赛(白蛋白结合型)(HB1801)用于HER2阳性晚期乳腺癌一线治疗的III期临床研究结果于2026年ESMO年会上以优选口头报告形式公布

智通财经
Oct 26
【石药集团(01093.HK):安尼妥单抗联合注射用多西他赛(白蛋白结合型)(HB1801)用于HER2阳性晚期乳腺癌一线治疗的III期临床研究结果于2026年ESMO年会上以优选口头报告形式公布】智通财经APP讯,石药集团(01093.HK)发布公告,集团与江苏康宁杰瑞生物制药有限公司合作开发的安尼妥单抗注射液(商品名:恩尼妥®)联合注射用多西他赛(白蛋白结合型)(HB1801)用于人表皮生长因子受体2(HER2)阳性晚期乳腺癌一线治疗的III期临床研究(研究编号:HEALER)的期中分析结果,已于2026年10月24日在2026年欧洲肿瘤内科学会(ESMO)年会上入选最新突破性摘要(Late-breaking Abstract, LBA),并以优选口头报告形式公布。同时,该研究同步以原创论文形式发表于《新英格兰医学杂志》(NEJM),成为中国内地乳腺癌临床领域首个发表于NEJM的成果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10